KRASG12C
A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients
Anika Sharma
D‐1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...
Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-Naïve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)
Anika Sharma
ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...
Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC
SG Tylor
Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced non–small cell lung cancer ...
